Gelardi M, Silvestri M, Ciprandi G
Section of Otolaryngology, Department of Basic Medical Science, Neuroscience and Sensory Organs, University of Bari, Italy
Istituto G. Gaslini, Genova, Italy
J Biol Regul Homeost Agents. 2018;32(1 Suppl. 2):21-28.
As LPR diagnostic work-up is complex in the absence of a definitive gold standard diagnostic test, patient symptoms have become a primary method to identify those with LPR. In this regard, Reflux Symptom Index (RSI) is a reliable self-administered questionnaire useful also to monitor changes after treatment. An Italian survey on patients with LPR evaluated the effect of treatments for LPR that were prescribed in a real-world setting, such as Otolaryngological clinics. In this part of the survey, 1,680 subjects [45.2% males, 54.8% females, 50.4 (14.7) years] were visited in the 86 Italian ORL centers. About 70% of patients were treated with Marial® alone, 27% with PPI plus add-on. RSI change assessment was the primary outcome. Both therapeutic options significantly (p<0.0001) reduced RSI score interestingly since the second week. The inter-group comparison demonstrated the Marial® monotherapy induced a greater reduction of RSI than PPI plus add-on since the second week. In conclusion, the present survey reported that a new medical device (Marial®) may be considered a valid option for the treatment of LPR.
由于在缺乏明确的金标准诊断测试的情况下，喉咽反流（LPR）的诊断检查很复杂，患者症状已成为识别LPR患者的主要方法。在这方面，反流症状指数（RSI）是一种可靠的自我管理问卷，也有助于监测治疗后的变化。一项针对LPR患者的意大利调查评估了在现实环境（如耳鼻喉科诊所）中开出的LPR治疗方法的效果。在该调查的这一部分中，86家意大利耳鼻喉科中心对1680名受试者[45.2%为男性，54.8%为女性，年龄50.4（14.7）岁]进行了诊治。约70%的患者仅接受马瑞尔（Marial®）治疗，27%的患者接受质子泵抑制剂（PPI）加附加治疗。RSI变化评估是主要结果。有趣的是，自第二周起，两种治疗方案均显著（p<0.0001）降低了RSI评分。组间比较表明，自第二周起，马瑞尔单药治疗比PPI加附加治疗导致RSI降低幅度更大。总之，本次调查表明，一种新型医疗设备（马瑞尔）可被视为治疗LPR的有效选择。
